Hope on the Horizon: TMCC & Haleigh’s Hope Join Hands to Expand CBD Access
Authored by Dean Sangalis (Executive Content Engineer, Karmik) & Gaurav Dubey (Lead Staff Writer, TMCC; Co-Founder/President, Karmik)
Hope on the Horizon: TMCC & Haleigh’s Hope Join Hands to Expand CBD Access
TMCC is pleased to announce their new partnership with Haleigh’s Hope. Jason Cranford, founder of the Flowering H.O.P.E. Foundation and the person responsible for the strain known globally as Haleigh’s Hope, has given families and individuals an incredible medicine, often when all else has failed. We are excited to be a part of the continuing effort to help people gain access to Haleigh’s Hope, a strain of Cannabis Sativa rich in cannabidiol (CBD), in all its forms—especially for the Lennox-Gastaut and Dravet community (two rare and insidious forms of childhood epilepsy1).
Founded in 2013, Haleigh’s Hope is named after Haleigh Cox, a young girl from Georgia whose severe epileptic seizures and further health complications seriously hindered her quality of living and overall life expectancy. Her parents, Janea and Brian, had exhausted their options before finding Jason, choosing to bring Haleigh to Colorado for treatment, where they wouldn’t be legally prosecuted. Her story is worth reading in full, as it is a testament to the impact of this company on many lives.
CBD Isolate Epidiolex Recently FDA Approved for Severe Childhood Epilepsy
Recently, the FDA approved a patented CBD solution called Epidiolex as a treatment for both Dravet Syndrome and Lennox-Gastaut Syndrome, which Haleigh was diagnosed with at age three. This decision follows high-quality studies proving the efficacy of CBD in treating epileptic seizures.2,3 However, Epidiolex is a pure CBD isolate and lacks a certain polypharmacy effect that is only associated with whole-plant cannabis extracts like Haleigh’s Hope.
Renowned cannabis scientist, Dr. Ethan Russo, has fiercely advocated for this polypharmacy effect, which is only observed with whole plant cannabis and their extracts and dubbed the “entourage effect.”4,5 It is this harmonious interplay among virtually infinite permutations of over sixty known cannabinoids (e.g. active compounds such as THC, CBD, CBN, etc…) and hundreds of cannabis-derived terpenes (e.g. linalool, beta-myrcene, etc…), which is thought to underscore the therapeutically robust and efficacious benefits of whole-plant medicine when compared to any single cannabinoid isolate, like Epidiolex.4,5 This is where Haleigh’s Hope truly shines.
A Cut Above the Rest: High-Quality, Broad Spectrum CBD Oil
Haleigh’s Hope (HH) is a proprietary strain of CBD-rich cannabis and the only strain used in their oils, ensuring maximum consistency and reduced variability (a difficult task with living medicine). It took seven years of careful breeding and cultivation to create the strain, and the oils produced by HH are rich in CBD, a compound that is now clinically proven to be efficacious in the treatment Dravet and Lennox-Gastaut epileptics.2,3 CBD is also known to be effective in the treatment of cancer, Crohn’s disease, and MS.6–8
However, unlike a prescription such as Epidiolex, HH oils contain far more active cannabinoids and terpenes, producing the more versatile entourage effect, and delivering more relief.
An Established Family Business
As a company, Haleigh’s Hope is a family business, owned and controlled by families of special needs children and Jason Cranford. They are vertically integrated, controlling the entire process from seed to sale, and they are a registered manufacturing lab with the Colorado Department of Public Health and the FDA. Since HH is a particular strain, the product is always consistent, and every batch of HH is lab tested for potency, microbes, pesticides, and solvents to ensure it is free of contaminants and standardized. Certificates of Analysis are available for every consumer, and all of their crops are USDA Organic Certified. Due to their patient-centered mission, their integrity is outstanding—as many testimonials illustrate—and they work in conjunction with the Flowering H.O.P.E. Foundation, which offers a low-income assistance program that helps with the purchase of HH products.
Haleigh’s Hope Advisory Board Consists of PhD’s in Neuroscience, Organic Chemistry
Haleigh’s Hope also has an advisory board consisting of PhD neuroscientists and organic chemists who help in the development and use of the product line. This ensures that those new to using HH have professional support in determining the correct dosage, along with a resource for questions and concerns.
Letting Others Sing Your Praises (So You Don’t Have To)
With CBD currently a buzz word, many new companies are attempting to gain footing in the community, capitalizing on the craze. HH was founded years prior to the “CBD Rush,” and they make no public medical claims on their website or labeling. CBD isn’t even listed on their labels so as to comply with FDA labelling requirements. Instead, they let news stories promote the success of their products—they have been featured on Vice, HBO, National Geographic, NBC, CBS, Fox, and CNN.
Haleigh’s Hope Used in Children’s Hospital and John Hopkins Studies
HH has been used in research studies performed at the Children’s Hospital and Johns Hopkins, and they are currently involved in two clinical research Institutional Review Board studies, one for autism and epilepsy with cannabinoids, and the other for traumatic brain injury with cannabinoids. Distributed within the United States and over 40 other counties, HH also offers free access to a support group of 6,000 worldwide members who are using their products.
Moving Forward, Making Change
During the Cox family’s struggle, Janea had reached out to Allen Peake, her state representative in Georgia, asking him to help legalize medical marijuana in the state. Janea moved with Haleigh to Colorado while Brian stayed in Georgia, working to support the family. Although rebuffed in 2014, in 2015 Georgia Governor Nathan Deal signed HB1, also known as the Haleigh’s Hope Act, into law, enabling the Cox family to reunite in Georgia, and marking a victory for medical cannabis.
The Major Caveat to GA’s 2015 HH Act and Why Expanded Access Is Necessary
In terms of cannabis policy, the Haleigh’s Hope Act is indeed a small glint of progress in an otherwise restrictive state, allowing registered Georgia residents to legally possess up to twenty ounces of low THC oil (maximum 5% THC).9,10 The caveat is that the oil is prohibited from being produced and distributed in Georgia, forcing patients who qualify to inevitably engage in illegal practices to obtain their medicine. Expanding legislation to allow production of such oil within state lines can eliminate illegal interstate transport of cannabis oil. TMCC’s partnership with the impassioned and dedicated leaders at Haleigh’s Hope aims to help expand access to their life-changing medicine for everyone.
We look forward to reshaping public opinion and sharing new stories together, as we continue to make change in our communities and the world. For more information regarding Haleigh’s Hope, patient testimonials, and their mission, follow the links below.11,12 If you or a loved one find yourselves wanting to explore Haleigh’s Hope as an option, you may use the code HHMCC to save on select products. Proceeds generated from your support will allow us to continue our mission to expand access for people all around the world.
- Rosenberg, E. C., Tsien, R. W., Whalley, B. J. & Devinsky, O. Cannabinoids and Epilepsy. Neurother. J. Am. Soc. Exp. Neurother. 12, 747–768 (2015).
- Do Val-da Silva, R. A. et al. Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy. Front. Pharmacol. 8, (2017).
- Stockings, E. et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J. Neurol. Neurosurg. Psychiatry 89, 741–753 (2018).
- Russo, E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 163, 1344–1364 (2011).
- Russo, E. B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro Endocrinol. Lett. 25, 31–39 (2004).
- Cannabidiol to Improve Mobility in People with Multiple Sclerosis. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874292/. (Accessed: 6th February 2019)
- Chakravarti, B., Ravi, J. & Ganju, R. K. Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget 5, 5852–5872 (2014).
- Naftali, T. et al. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 11, 1276-1280.e1 (2013).
- Haleigh’s Hope: A Mother’s Unexpected Journey to the Front Lines of Marijuana Advocacy. Compassionate Certification Centers (2017).
- CBD Oil in Georgia [2019 Update]. MarijuanaBreak (2019).
- Haleigh’s HopeTM. Haleigh’s Hope Available at: https://haleighshope.com/. (Accessed: 29th January 2019)
- Home. Available at: http://www.floweringhope.co/index.html. (Accessed: 6th February 2019)